. 2015 Oct 19;14:414. doi: 10.1186/s12936-015-0933-7

Table 4.

General characteristics and understanding of anti-malarial treatment intake in the exit interview study population

	Patients (n = 120) [n (%)]	Caretakers (n = 92) [n (%)]
Age (years)
<5	43 (35.8)	–
≥5	77 (64.2)	92 (100.0)
Mean, median (minimum–maximum) (years)	10, 5 (0–60)	28, 27 (10–68)
Gender
Male	64 (53.3)	9 (9.8)
Female	56 (46.7)	83 (90.2)
Highest education level
Illiterate	3/28^a (10.7)	17/91^b (18.7)
Primary level	12/28^a (42.9)	37/91^b (40.6)
Secondary level	12/28^a (42.9)	35/91^b (38.5)
Higher level	1/28^a (3.5)	2/91^b (2.2)

	n	[%]
Perception of disease (n = 120)
Able to name disease as malaria	33	27.5
Able to name signs/symptoms of malaria	72	60.0
Disease and its signs/symptoms unknown or other symptoms mentioned	15	12.5
Perception of anti-malarial treatment (n = 120)
Able to show FDC ASAQ as only malaria treatment	97	80.8
Able to show FDC ASAQ together with paracetamol	10	8.3
Shows only paracetamol	2	1.7
Unable to distinguish any given treatment	11	9.2

	n/N	[%]
Patient or caretaker of patient
Was able to correctly repeat the instructions for FDC ASAQ intake	107/120	89.2
Errors made while repeating the instructions for FDC ASAQ intake	13/120	10.8
Second dose will be wrongly taken at first intake day in the evening	6/13	46.2
Split dose in half and take first half in the morning and second half in the evening	4/13	30.8
Unable to repeat instructions	2/13	15.4
Will start with FDC ASAQ the next day (first dose was not given at OPD)	1/13	7.7
Will continue with treatment although patient feels better the next day	114/120	95.0
OPD role
Was asked in the OPD if she/he had understood instructions	87/120	72.5
Was asked to repeat instructions	39/120	32.5
Was given additional information related to FDC ASAQ	43/120	35.8

FDC ASAQ fixed-dose combination artesunate–amodiaquine, OPD outpatient department

^aNumber of patients who came to the OPDs without a caretaker

^b1 missing value